Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Sam who wrote (137)	4/1/1998 11:28:00 AM
From: geewiz	Respond to of 534

Sam, News of Peggy Millers' resignation is a suprise; she's been with the company since before Jim O'Shea. However I am about as confident as I can be that the numbers and revenue recording were not involved; our most recent quarterly was delayed several weeks so the auditors could approve it. Quarterly numbers are not always run past the auditors, this can lead to adjustment when the annual numbers are reported and its' my guess O'Shea wanted to eliminate this potential problem. Good news for BJCT this morning: biz.yahoo.com If BDX quit CYGN, who are they planning to team with? "Changes that have occured in the glucose monitoring field since the agreement was signied two years ago". Patient-friendly glucose monitoring is essential to their strategy. best, art